A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 23-Year-Old Women.

Trial Profile

A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 23-Year-Old Women.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant octavalent Merck (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 19 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Aug 2008 Added official title, patient numbers and secondary identifier (V502-001) as reported by ClinicalTrials.gov.
    • 18 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top